Cure8 research brief
This abstract reports that etrasimod improved multiple measures of disease activity versus placebo in patients who had inadequate response to conventional UC therapies, indicating it may be a useful first-line advanced oral option early in treatment.
Adults with ulcerative colitis considering advanced (non-biologic oral) therapies, gastroenterologists treating UC, and patients previously treated with 5-ASA, corticosteroids, or thiopurines.
This report summarizes prespecified and post hoc subgroup analyses from the phase III ELEVATE UC trials (ELEVATE UC 52 and ELEVATE UC 12). In patients whose disease had not responded sufficiently to 5-ASA alone, etrasimod 2 mg once daily led to higher rates of clinical, endoscopic, and histologic endpoints versus placebo at both week 12 and week 52.
Pooled analyses of patients previously exposed to 5-ASA plus corticosteroids also favored etrasimod at both time points. In the smaller subgroup with prior thiopurine exposure, statistically significant differences were seen at week 12 and numerical (non-significant) differences at week 52.
Safety findings in the subgroups were reported as similar to the overall trial population; the abstract does not list specific adverse events here. The trials referenced are registered on ClinicalTrials.gov (NCT03945188, NCT03996369), and the article content provided is an abstract-level summary.
If you are considering treatment options, discuss with your gastroenterologist how trial populations and eligibility compare with your situation; this abstract reports subgroup analyses rather than individualized treatment recommendations.
These are subgroup analyses from phase III trials summarized in an abstract. Results are promising but are presented at the abstract level here; full trial publications and safety details should be reviewed. Subgroup (post hoc) analyses can be less definitive than prespecified primary analyses.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: David T. Rubin: Grant support from Takeda and Pfizer; consultant for AbbVie, Abivax SA, Altrubio, Athos Therapeutics Inc, Bristol Myers Squibb, Celltrion, Connect BioPharma, Eli Lilly & Co, Genentech (Roche) Inc, Iterative Health, Janssen Pharmaceuticals, Johnson & Johnson, Merck & Co, Mirador, Odyssey Therapeutics, Pfizer Inc, Sanofi, Spyre, Takeda Pharmaceuticals, Vedanta Biosciences, and Ventyx. Charlie W. Lees: Consultancy and/or speaker fees from AbbVie, Pfizer Inc, Takeda, Janssen, Gilead, Galapagos, Alfa Sigma, Dr Falk Fresnius Kabi, and Ferring. Filip Baert: Financial support for research/grants: AbbVie, Amgen, Eurogenerics, Janssen, and Takeda. Lecture fees/speaker’s bureau: AbbVie, Arena Pharmaceuticals, Celltrion, Ferring, Galapagos, Janssen, Merck Sharp & Dohme, Pfizer Inc, and Takeda. Consultancy: AbbVie, Abivax, Amgen, Arena Pharmaceuticals, Celgene, Celltrion, Ferring, Fresenius Kabi, Janssen, Merck Sharp & Dohme, Pfizer Inc, and Sandoz. Grant support: Eurogenerics. Maria Kudela: Employee and shareholder of Pfizer Inc. Abhishek Bhattacharjee: Employee of Pfizer Healthcare India Pvt. Ltd. and shareholder of Pfizer Inc. Krisztina Lazin: Employee of Pfizer AG and shareholder of Pfizer Inc. Martina Goetsch: Employee of Pfizer AG and shareholder of Pfizer Inc. Arcangelo M. Abbatemarco: Employee and shareholder of Pfizer Inc. Karolina Wosik: Employee of Pfizer Canada and shareholder of Pfizer Inc. John K. Marshall: Fees for consulting and/or speaking from AbbVie, Alimentiv, Amgen, Avir Pharma, Biocon, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, GlaxoSmithKline, Janssen, Lilly, Organon, Pfizer Inc, Pharmascience, Regeneron, Roche, Sandoz, Sanofi, and Takeda.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory...
This registry will provide real-world data on how etrasimod is used and performs in routine clinical practice in China, including patient characteristics, symptom trajectories, safety, and healthcare costs. Real-world...
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
